Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 5, 2007

View Archived Issues

Novel candidate gene for Parkinson's disease identified

Treatment option for opioid dependency imparted in recent Reckitt Benckiser patent

New coagulation factor VIIa inhibitors disclosed in recent Eisai patent

Recent GSK and Mochida patents report novel analgesic agents

Studies detail efficacy of sugammadex in reversing neuromuscular blockade

DTS-201 safe in first-in-man study

In vivo antinociceptive effects reported for novel alpha2-adrenoceptor agonist

New gene associated with cardiovascular disease identified

Novel compounds overcome drug resistance in tumors expressing BCRP

Preclinical and clinical profile of BIIB-021, an Hsp90 inhibitor with antitumor activity

Antitumor effects seen with JX-594 in patients with liver tumors

MGCD-0103 and gemcitabine given in combination to patients with solid tumors

Santhera reports positive results from phase IIa trial of SNT-MC17

Ono and Medarex file IND for MDX-1106/ONO-4538 for hepatitis C

Eisai delays filing of regulatory submission of E-2007 until the fourth quarter of 2008

Cytokine reports oral efficacy of anti-cytokine semapimod

Taisho and Pfizer sign letter of intent for schizophrenia drug candidate

Tranzyme initiates phase IIb TZP-101 trial for severe gastroparesis

Lev amends Cinryze BLA for the treatment of hereditary angioedema

Vanda presents top-line results of phase II trial of VSF-173 for excessive sleepiness

Clinuvel initiates phase II trials of CUV-1647 for sun damage and actinic keratosis

Addrenex and Sciele initiate phase III trials for Clonicel

Enzon initiates phase I study of EZN-2968 to evaluate additional dosing schedule

Neoprobe and FDA agree on design of phase III trials for Lymphoseek

BioLineRx presents positive results from phase IIa interim trial of BL-1020 for schizophrenia

FDA accepts Indevus Pharmaceuticals' NDA for Nebido for male hypogonadism

FDA issues a not approvable letter for gepirone extended-release tablets

Trophos reports clinical results for TRO-19622 in patients with ALS

First U.S. clinical results for Avigen's antispastic agent AV-650

Noninvasive NGF-based therapies for Alzheimer's disease described by Italian investigators

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026